{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-150146","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2022-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.937191+00:00","generated_at":"2026-06-25T17:06:28.580143+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"CFO Keith Vendola departs; Brian Burkavage appointed Chief Accounting Officer","bullets":["Keith Vendola terminated as CFO by mutual agreement effective May 9, 2022; no disagreement with company or board.","CEO Mai-Britt Zocca will serve as Principal Financial Officer until CAO appointment.","Brian Burkavage, previously VP of Finance, appointed Chief Accounting Officer effective May 12, 2022.","Burkavage was Controller at Passage BIO (2020-2021) and Director of FP&A at Aclaris Therapeutics (2017-2020)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-150146","json":"https://secwatch.observer/filing/0001193125-22-150146.json","markdown":"https://secwatch.observer/filing/0001193125-22-150146.md","text":"https://secwatch.observer/filing/0001193125-22-150146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522150146/0001193125-22-150146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522150146/d339835d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T17:06:28.580143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"375b266821","claim":"Brian Burkavage was appointed as Chief Accounting Officer at IO Biotech, Inc..","evidence_excerpt":"On May 12, 2022, the Company appointed Brian Burkavage, 39, the Company’s Vice President of Finance, as its Chief Accounting Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522150146/0001193125-22-150146-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"99b1770a78","claim":"Keith Vendola was terminated as Chief Financial Officer at IO Biotech, Inc..","evidence_excerpt":"On May 9, 2022, IO Biotech, Inc. (the “Company”) and Keith Vendola, Chief Financial Officer of the Company, have terminated Mr. Vendola’s employment with the Company by mutual agreement, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522150146/0001193125-22-150146-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}